Home > Compound List > Product Information
Calcium Acetate_Molecular_structure_CAS_62-54-4)
Click picture or here to close

Calcium Acetate

Catalog No. DB00258 Name DrugBank
CAS Number 62-54-4 Website http://www.ualberta.ca/
M. F. C4H6CaO4 Telephone (780) 492-3111
M. W. 158.16604 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 143

SYNONYMS

IUPAC name
calcium diacetate
IUPAC Traditional name
calcium(2+) bis(acetate ion)
Brand Name
Calac
Sorbo-calcian
Niacet calcium acetate tech
PhosLo
PhosLo Gelcaps
Sorbo-calcion
Teltozan
Synonyms
Gray acetate of lime
Calcium acetate hydrate
Grey acetate
Acetic acid, calcium salt
Brown acetate
Brown acetate of lime
Calcium acetate monohydrate
Gray acetate
Procalamine
Vinegar salts
Calcium diacetate
Lime acetate
Lime pyrolignite
Pyrolignite of lime

DATABASE IDS

PubChem CID 6116
PubChem SID 46507985
CAS Number 62-54-4

PROPERTIES

DETAILS

Description (English)
Item Information
Drug Groups approved
Description The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]
Indication Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
Pharmacology Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Toxicity Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected Organisms
Humans and other mammals
Absorption 40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Elimination Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
External Links
Wikipedia
Drugs.com

REFERENCES